ArticlePloS one2025
Trends and projections of polycystic ovary syndrome burden in China: Insights from the Global Burden of Disease Study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a prevalent endocrine disorder among women of reproductive age, associated with reproductive, metabolic, and psychological complications. In China, the burden of PCOS remains poorly characterized, particularly amid changing demographics and lifestyle patterns. This study evaluates trends in PCOS incidence, prevalence, and disability-adjusted life-years (DALYs) from 1990 to 2021 and projects the future burden through 2035.
methodsData on PCOS incidence, prevalence, and DALYs for Chinese women aged 10-54 years were extracted from the Global Burden of Disease Study 2021. Age-specific and age-standardized rates were calculated. Temporal trends were assessed using estimated annual percentage changes (EAPCs), and decomposition analysis quantified contributions of epidemiological changes, population growth, and aging. Projections through 2035 were based on current trends.
resultsFrom 1990 to 2021, PCOS incidence and prevalence showed significant increases, especially in younger age groups. Among 10-14-year-olds, incidence rose from 73,615 cases (95% UI: 35,399-124,529) to 128,219 cases (95% UI: 65,776-211,113), while prevalence increased from 124,220 (95% UI: 59,649-211,274) to 216,398 cases (95% UI: 110,028-357,026). Age-standardized rates are projected to rise to 70.82 (95% CI: 45.39-96.26) and 1,661.80 (95% CI: 1,467.99-1,855.62) per 100,000 by 2035, respectively. Decomposition analysis showed epidemiological changes as the primary driver of increased burden.
conclusionsThe burden of PCOS in China has risen substantially over three decades and is projected to escalate further. Marked increases in PCOS incidence and prevalence were observed among younger age groups, indicating an earlier onset or diagnosis. These findings highlight a shifting burden toward younger age groups and underscore the importance of age-specific surveillance and prevention strategies to address the evolving epidemiology of PCOS in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.